Emcitate (tiratricol)

Name: Emcitate (tiratricol) in MCT8 deficiency: American hospital formulary service (AHFS), or other drug classification
Published: 2026-09-14T15:39:06-04:00

MCT8 deficiency

Manufacturer: Egetis Therapeutics
Regulatory submission: NDA submitted January 2026 and approved September 2026
Launch: Anticipated eight to ten weeks after the September 2026 approval
Last updated: September 29, 2026

Section

Product information and disease description Product description Product information

American hospital formulary service (AHFS), or other drug classification

1 evidence topic · 1 source

ATC classification

Field	Quoted record
Anatomical therapeutic chemical (ATC) code	“H03AA04”
Pharmacotherapeutic group	“Thyroid therapy”